Orchestra BioMed Announces Appointment of Former Medtronic SVP of Corporate Development Christopher Cleary to Board of Directors Medical device industry veteran brings over three decades of expertise in M&A, as well as s

Orchestra BioMed Announces Appointment of Former

Medtronic SVP of Corporate Development Christopher Cleary to Board of Directors

NEW HOPE, PA, February 5, 2025 (GLOBE NEWSWIRE)

-- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, "Orchestra BioMed" or the "Company"), a biomedical company accelerating

high-impact technologies to patients through risk-reward sharing partnerships, today announced the appointment of Christopher Cleary to

its Board of Directors as an independent member, effective as of January 30, 2025. Mr. Cleary brings over three decades of experience

in corporate development, mergers, acquisitions, strategic investments and structured R&D collaborations, having significantly impacted

the medical technology industry through his strategic leadership and visionary approach.

"We're thrilled to welcome Chris as

an independent member of the Orchestra BioMed Board of Directors, a role in which we expect he will provide invaluable guidance to help

us more effectively execute our novel, partnership-enabled business model," said David Hochman, Chairman, Chief Executive Officer

and Founder of Orchestra BioMed. "We got to know Chris well over the last several years as he played a key role in shaping our strategic

collaboration with Medtronic. With his extensive experience in global strategy, dealmaking, investing, and partnering, Chris brings knowledge

and experience that is directly relevant to our strategy, technologies, and pathways to success. He shares our vision that risk-reward

sharing partnerships can be a powerful tool for advancing high-impact medical device innovations like AVIM therapy and Virtue SAB and

we are excited to work closely with him on our Board."

Mr. Cleary commented, "I am excited to join

the Orchestra BioMed Board of Directors and contribute to the Company's bold mission of accelerating medical device innovation in

cardiovascular disease through strategic partnerships. I believe their pioneering approach addresses key challenges limiting leading corporations'

abilities to deploy financial and operational resources to directly drive the development of promising high-impact device-based therapies.

Orchestra BioMed's collaboration with Medtronic for AVIM therapy, which I had the opportunity to help shape, is a great example

of this business at work. I look forward to working with the experienced Board of Directors and entire Orchestra BioMed team to continue

driving groundbreaking advancements in cardiovascular medicine like AVIM therapy, Virtue SAB and beyond."

During his time as SVP of Corporate

Development at Medtronic, Mr. Cleary facilitated over 35 acquisitions and multiple structured and venture investments and

orchestrated the $6 billion sale of Covidien Group S. .r.l 's medical supply assets to Cardinal Health Inc (NYSE: CAH). His

strategic acumen and negotiation skills helped drive Medtronic's growth and market expansion. Before joining Medtronic, Chris

was the CEO of Alesia Capital Services, a management consulting firm for Fortune 500 companies, including Medtronic, Goldman Sachs,

Ally, Macquarie Capital and Terex. He also led M&A teams within several businesses at GE Capital, closing acquisitions totaling

more than $60 billion across 200+ transactions in the US, Canada, Europe, Asia and Latin America. Mr. Cleary also currently serves

on the Board of Enterra Medical, Inc., and Pristine Surgical LLC. Mr. Cleary earned his B.A. in Biology from Colorado College.

After seven years of dedicated service on Orchestra

BioMed's Board of Directors, Eric A. Rose, M.D. will transition to Board Member Emeritus and Strategic Advisor to Orchestra BioMed.

This new role will allow Dr. Rose to continue contributing his wealth of industry expertise, supporting key initiatives and long-term

objectives. His leadership has been instrumental in helping shape the Company's growth and will remain a valuable asset in this advisory

About Orchestra BioMed

Orchestra BioMed (Nasdaq: OBIO) is a biomedical

innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships with leading medical device

companies. Orchestra BioMed's partnership-enabled business model focuses on forging strategic collaborations with leading medical

device companies to drive successful global commercialization of products it develops. Orchestra BioMed's lead product candidate

is atrioventricular interval modulation (AVIM) therapy for the treatment of hypertension, a significant risk factor for death worldwide.

Orchestra BioMed is also developing the Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of

atherosclerotic artery disease, the leading cause of mortality worldwide. Orchestra BioMed has a strategic collaboration with Medtronic,

one of the largest medical device companies in the world, for development and commercialization of AVIM therapy for the treatment of

hypertension in pacemaker-indicated patients, and a strategic partnership with Terumo, a global leader in medical technology, for development

and commercialization of Virtue SAB for the treatment of artery disease. For further information about Orchestra BioMed, please visit www.orchestrabiomed.com,

References to Websites and Social Media Platforms

References to information included on, or accessible through, websites and social media platforms do not constitute incorporation by reference

of the information contained at or available through such websites or social media platforms, and you should not consider such information

to be part of this press release.

AVIM therapy is an investigational therapy compatible

with standard dual-chamber pacemakers designed to substantially and persistently lower blood pressure. It has been evaluated in pilot

studies in patients with hypertension who are also indicated for a pacemaker. MODERATO II, a double-blind, randomized, pilot study, showed

that patients treated with AVIM therapy experienced net reductions of 8.1 mmHg in 24-hour ambulatory systolic blood pressure (aSBP) and

12.3 mmHg in office systolic blood pressure (oSBP) at six months when compared to control patients. The BACKBEAT (BradycArdia paCemaKer

with atrioventricular interval modulation for Blood prEssure treAtmenT) global pivotal study will further evaluate the safety and efficacy

of AVIM therapy in lowering blood pressure in a similar target population of patients who have been indicated for, and recently implanted

with, a dual-chamber cardiac pacemaker.

Forward-Looking Statements

Certain statements included in this press

release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United

States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as

"believe," "may," "will," "estimate," "continue,"

"anticipate," "intend," "expect," "should," "would," "plan,"

"predict," "potential," "seem," "seek," "future," "outlook"

and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These

forward-looking statements include, but are not limited to, statements relating to the potential efficacy, safety and commercial

value of the Company's commercial product candidates, the ability of the Company's partnerships to accelerate clinical

development, and the Company's late-stage development programs and strategic partnerships. These statements are based on

various assumptions, whether or not identified in this press release, and on the current expectations of the Company's

management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes

only and are not intended to serve as and must not be relied on as a guarantee, an assurance, a prediction, or a definitive

statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and may differ from

assumptions. Many actual events and circumstances are beyond the control of the Company. These forward-looking statements are

subject to a number of risks and uncertainties, including changes in domestic and foreign business, market, financial, political,

and legal conditions; risks related to regulatory approval of the Company's product candidates and ongoing regulation of the

Company's product candidates, if approved; the timing of, and the Company's ability to achieve, expected regulatory and

business milestones; the impact of competitive products and product candidates; and the risk factors discussed under the heading

"Item 1A. Risk Factors" in the Company's annual report on Form 10-K for the year ended December 31, 2023, which

was filed with the U.S. Securities and Exchange Commission on March 27, 2024, as updated by any risk factors disclosed under the

heading "Item 1A. Risk Factors" in the Company's subsequently filed quarterly reports on Form 10-Q.

The Company operates in a very competitive

and rapidly changing environment. New risks emerge from time to time. Given these risks and uncertainties, the Company cautions against

placing undue reliance on these forward-looking statements, which only speak as of the date of this press release. The Company does not

plan and undertakes no obligation to update any of the forward-looking statements made herein, except as required by law.